Hospital
Salt Lake Regional Medical Center LP
Salt Lake Regional Medical Center LP was paid $9.78M by Medicaid between Jan 2018 and Apr 2023, across 128 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 74% of everything it billed.
33Billing provider infoSALT LAKE REGIONAL MEDICAL CENTER LP
SALT LAKE CITY, UT 84102
SALT LAKE CITY, UT 84102
33aNPI1417988833assigned 07/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.78M
24GClaims170,464
24DCodes billed128
24AFirst – last monthJan 2018 – Apr 2023
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#11 of 26
Median peer was paid$6.14M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,961 | $1.26M | |
| 2019 | 32,163 | $1.33M | |
| 2020 | 31,836 | $2.02M | |
| 2021 | 41,290 | $2.64M | |
| 2022 | 36,387 | $2.42M | |
| 2023 | 1,827 | $106K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 74% | 26,327 | 7,242 | $7.22M |
| 36415 | Collection of venous blood by venipuncture | 15% | 12,962 | 10,132 | $1.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.0% | 6,517 | 5,712 | $293K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.1% | 6,319 | 5,495 | $108K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 1,787 | 1,574 | $106K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,101 | 1,858 | $88K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 5,831 | 4,972 | $58K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,211 | 1,064 | $54K |
| 80047 | <1% | 1,435 | 1,240 | $39K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,299 | 3,617 | $39K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 747 | 691 | $38K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,736 | 2,309 | $26K |
116 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 829 | $25K |
| 97597 | <1% | 315 | $20K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,818 | $20K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 727 | $20K |
| 82962 | <1% | 914 | $14K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,608 | $14K |
| 81003 | <1% | 2,328 | $13K | |
| 84703 | <1% | 1,634 | $11K | |
| 80053 | Comprehensive metabolic panel | <1% | 7,006 | $10K |
| 84484 | <1% | 2,992 | $9K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 978 | $9K |
| 81001 | <1% | 2,880 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 290 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 971 | $7K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,175 | $6K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,121 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 1,024 | $5K |
| 81025 | <1% | 735 | $5K | |
| 87081 | <1% | 162 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 123 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,047 | $5K |
| 87088 | <1% | 832 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,899 | $4K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,863 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,475 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 167 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 553 | $3K |
| 81002 | <1% | 60 | $2K | |
| 87077 | <1% | 403 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 29 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,871 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 30 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 558 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 742 | $2K |
| 85610 | <1% | 1,652 | $2K | |
| 73610 | <1% | 14 | $2K | |
| A9270 | Non-covered item or service | <1% | 5,533 | $1K |
| 80320 | <1% | 984 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,944 | $1K |
| 85730 | <1% | 1,003 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 470 | $1K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,696 | $1K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 35 | $1K |
| 83605 | <1% | 1,485 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,919 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 36 | $938.61 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 61 | $929.48 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 63 | $912.36 |
| J3490 | Unclassified drugs | <1% | 47 | $857.27 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 928 | $848.72 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 161 | $817.37 |
| 80050 | General health panel | <1% | 1,079 | $768.61 |
| 10060 | <1% | 16 | $760.91 | |
| 83690 | <1% | 2,175 | $732.61 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,621 | $670.62 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 205 | $644.76 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 355 | $603.87 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 502 | $583.07 |
| 80179 | <1% | 450 | $582.11 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $581.02 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 81 | $564.72 |
| 87070 | <1% | 15 | $517.23 | |
| 87503 | <1% | 19 | $513.09 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 770 | $500.53 |
| 80076 | <1% | 613 | $488.39 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 24 | $417.46 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 718 | $387.00 |
| 87186 | <1% | 500 | $238.11 | |
| 83735 | <1% | 840 | $236.52 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 46 | $204.66 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,645 | $195.69 |
| 82553 | <1% | 15 | $165.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 654 | $87.20 |
| 82550 | <1% | 746 | $42.14 | |
| 83880 | <1% | 175 | $33.55 | |
| 59025 | Fetal non-stress test | <1% | 21 | $29.75 |
| 85379 | <1% | 12 | $8.20 | |
| 96376 | <1% | 423 | $7.34 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 18 | $5.37 |
| 86140 | <1% | 52 | $4.14 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 33 | $3.86 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 365 | $2.53 |
| 85652 | <1% | 39 | $2.16 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,266 | $0.93 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 13 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,563 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 799 | $0.00 |
| 87040 | 0% | 341 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 146 | $0.00 |
| 82077 | 0% | 938 | $0.00 | |
| 94760 | 0% | 476 | $0.00 | |
| 87205 | 0% | 28 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 32 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 15 | $0.00 |
| 85027 | 0% | 62 | $0.00 | |
| 80329 | 0% | 45 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 30 | $0.00 |
| 94762 | 0% | 20 | $0.00 | |
| 86710 | 0% | 20 | $0.00 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 12 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 21 | $0.00 |
| 85651 | 0% | 13 | $0.00 | |
| 82607 | 0% | 15 | $0.00 | |
| 80143 | 0% | 451 | $0.00 | |
| 97161 | 0% | 50 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 130 | $0.00 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 20 | $0.00 |
| 82947 | 0% | 16 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 20 | $0.00 |
| J1645 | Injection, dalteparin sodium, per 2500 iu | 0% | 29 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 66 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 14 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 53 | $0.00 |
| 80061 | Lipid panel | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNS, DALE (HOSPITAL CEO)